Aristeia Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Aristeia Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-12,400	Closed	-$1.05M	–	88
2019 Q4	$1.05M	Hold	12,400	–	–	0.07%	43
2019 Q3	$836K	Sell	12,400 -1,200	-9%	-$92.4K	0.05%	53
2019 Q2	$1.17M	Sell	13,600 -25,200	-65%	-$2.16M	0.05%	54
2019 Q1	$3.45M	Buy	+38,800	New	+$3.6M	0.19%	39

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Aristeia Capital's BMRN Position: Q1 2020 in Review

Aristeia Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2020, closing a stake of 12,400 shares — an estimated $1.05M sold.

Aristeia Capital first reported a position in BMRN in Q1 2019 and held it in 4 quarters. The position peaked at $3.45M in Q1 2019. 500 funds tracked by Wall St. Rank hold BMRN as of Q1 2020.

Aristeia Capital reported no remaining BioMarin Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Aristeia Capital sold 12,400 BioMarin Pharmaceuticals shares in Q1 2020, an estimated $1.05M.
Aristeia Capital first reported a position in BioMarin Pharmaceuticals in Q1 2019 and held it in 4 quarters.
Aristeia Capital's BioMarin Pharmaceuticals position peaked at $3.45M in Q1 2019.
500 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2020.

Based on Aristeia Capital's 13F filing for Q1 2020, filed 15 May 2020.